Finally, with the development of therapies targeting angiogenesis, pretreatment ANGPTL7 levels might help select patients who are most likely to benefit from such proangiogenic therapies, paving the way for a more personalized approach in managing CHD. Here, ANGPTL7 is linked to coronary artery disorder.